Zobrazeno 1 - 10
of 148
pro vyhledávání: '"John H. Eldridge"'
Autor:
Demetrius Matassov, Lisa Evans DeWald, Stefan Hamm, Rebecca M. Nowak, Cheryl S. Gerardi, Theresa E. Latham, Rong Xu, Amara Luckay, Tracy Chen, Marc Tremblay, Jeffry Shearer, Melissa Wynn, John H. Eldridge, Kelly Warfield, Kevin Spurgers
Publikováno v:
Vaccines, Vol 12, Iss 8, p 858 (2024)
There are currently no prophylactic vaccines licensed to protect against Lassa fever caused by Lassa virus (LASV) infection. The Emergent BioSolutions (EBS) vaccine candidate, EBS-LASV, is being developed for the prevention of Lassa fever. EBS-LASV i
Externí odkaz:
https://doaj.org/article/5ac6e9310ddd44a58999bee90fd7b27a
Autor:
Courtney Woolsey, Robert W Cross, Krystle N Agans, Viktoriya Borisevich, Daniel J Deer, Joan B Geisbert, Cheryl Gerardi, Theresa E Latham, Karla A Fenton, Michael A Egan, John H Eldridge, Thomas W Geisbert, Demetrius Matassov
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 16, Iss 5, p e0010433 (2022)
BackgroundMarburg virus (MARV), an Ebola-like virus, remains an eminent threat to public health as demonstrated by its high associated mortality rate (23-90%) and recent emergence in West Africa for the first time. Although a recombinant vesicular st
Externí odkaz:
https://doaj.org/article/03f5f518f8bc426ba64de4f125e7cfd9
Autor:
Lukkana Suksanpaisan, Rong Xu, Mulu Z. Tesfay, Carolyn Bomidi, Stefan Hamm, Rianna Vandergaast, Nathan Jenks, Michael B. Steele, Ayuko Ota-Setlik, Hinna Akhtar, Amara Luckay, Rebecca Nowak, Kah Whye Peng, John H. Eldridge, David K. Clarke, Stephen J. Russell, Rosa Maria Diaz
Publikováno v:
Molecular Therapy: Oncolytics, Vol 10, Iss , Pp 1-13 (2018)
Immunotherapy for HPVPOS malignancies is attractive because well-defined, viral, non-self tumor antigens exist as targets. Several approaches to vaccinate therapeutically against HPV E6 and E7 antigens have been adopted, including viral platforms suc
Externí odkaz:
https://doaj.org/article/3396dace4a2548be8e2c17cb86f01e32
Autor:
Courtney Woolsey, Viktoriya Borisevich, Krystle N Agans, Rachel O’Toole, Karla A Fenton, Mack B Harrison, Abhishek N Prasad, Daniel J Deer, Cheryl Gerardi, Nneka Morrison, Robert W Cross, John H Eldridge, Demetrius Matassov, Thomas W Geisbert
Publikováno v:
The Journal of Infectious Diseases.
Background The family Filoviridae consists of several virus members known to cause significant mortality and disease in humans. Among these, Ebola virus (EBOV), Marburg virus (MARV), Sudan virus (SUDV), and Bundibugyo virus (BDBV) are considered the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8bea161e8dedaa898d114c294fbfd820
https://doi.org/10.1093/infdis/jiad157
https://doi.org/10.1093/infdis/jiad157
Autor:
Marnie L Elizaga, Shuying S Li, Nidhi K Kochar, Gregory J Wilson, Mary A Allen, Hong Van N Tieu, Ian Frank, Magdalena E Sobieszczyk, Kristen W Cohen, Brittany Sanchez, Theresa E Latham, David K Clarke, Michael A Egan, John H Eldridge, Drew Hannaman, Rong Xu, Ayuko Ota-Setlik, M Juliana McElrath, Christine Mhorag Hay, NIAID HIV Vaccine Trials Network (HVTN) 087 Study Team
Publikováno v:
PLoS ONE, Vol 13, Iss 9, p e0202753 (2018)
BACKGROUND:The addition of plasmid cytokine adjuvants, electroporation, and live attenuated viral vectors may further optimize immune responses to DNA vaccines in heterologous prime-boost combinations. The objective of this study was to test the safe
Externí odkaz:
https://doaj.org/article/799ab45103694bff91a425fb6ec10484
Autor:
Robert W. Cross, Rong Xu, Susan E. Witko, Ayuko Ota-Setlik, Lena Soukieh, Thomas W. Geisbert, Amara Luckay, Karla A. Fenton, Daniel J. Deer, Krystle N. Agans, John H. Eldridge, Theresa E. Latham, Chad E. Mire, Demetrius Matassov, Heinz Feldmann, Rebecca M. Nowak, Joan B. Geisbert, Christian T. Happi, Cheryl S. Gerardi, Stefan Hamm
Publikováno v:
Journal of Clinical Investigation. 130:539-551
Recent occurrences of filoviruses and the arenavirus Lassa virus (LASV) in overlapping endemic areas of Africa highlight the need for a prophylactic vaccine that would confer protection against all of these viruses that cause lethal hemorrhagic fever
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ff5e32f0f3faea9c6d40d076939d119
https://doi.org/10.1172/jci131958
https://doi.org/10.1172/jci131958
Autor:
Juliet Mpendo, Gaudensia Mutua, Julien Nyombayire, Rosine Ingabire, Annet Nanvubya, Omu Anzala, Etienne Karita, Peter Hayes, Jakub Kopycinski, Len Dally, Drew Hannaman, Michael A Egan, John H Eldridge, Kristen Syvertsen, Jennifer Lehrman, Beth Rasmussen, Jill Gilmour, Josephine H Cox, Patricia E Fast, Claudia Schmidt
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0134287 (2015)
Strategies to enhance the immunogenicity of DNA vaccines in humans include i) co-administration of molecular adjuvants, ii) intramuscular administration followed by in vivo electroporation (IM/EP) and/or iii) boosting with a different vaccine. Combin
Externí odkaz:
https://doaj.org/article/0b098e849d5f4436a0633fd93265da8e
Autor:
Marc Gurwith, Antony S. Dimitrov, Susan Sciotto-Brown, Stefan Hamm, Robert T. Chen, Emily R. Smith, Rong Xu, Luz Hermida, Tracy Chen, Marc Tremblay, Michael A. Egan, John H. Eldridge, Demetrius Matassov
Publikováno v:
Vaccine. 39(38)
Auro Vaccines LLC has developed a protein vaccine to prevent disease from Nipah and Hendra virus infection that employs a recombinant soluble Hendra glycoprotein (HeV-sG) adjuvanted with aluminum phosphate. This vaccine is currently under clinical ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0ecdc6cfe2be6345c231309d54bd8de
https://pubmed.ncbi.nlm.nih.gov/34373117
https://pubmed.ncbi.nlm.nih.gov/34373117
Autor:
Karla A. Fenton, Ilhem Messaoudi, Robert W. Cross, Daniel J. Deer, Courtney Woolsey, Cheryl S. Gerardi, Joan B. Geisbert, Viktoriya Borisevich, Thomas W. Geisbert, John H. Eldridge, Demetrius Matassov, Krystle N. Agans, Allen Jankeel, Theresa E. Latham, Chad E. Mire
Publikováno v:
Scientific Reports
Scientific Reports, Vol 10, Iss 1, Pp 1-18 (2020)
Scientific Reports, Vol 10, Iss 1, Pp 1-18 (2020)
Postexposure immunization can prevent disease and reduce transmission following pathogen exposure. The rapid immunostimulatory properties of recombinant vesicular stomatitis virus (rVSV)-based vaccines make them suitable postexposure treatments again
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f918431681c3f684b30842324b11ca9
https://pubmed.ncbi.nlm.nih.gov/32080323
https://pubmed.ncbi.nlm.nih.gov/32080323
Autor:
David K. Clarke, Theresa E. Latham, Michael A. Egan, Amara Luckay, Lucy A. Ward, Ayuko Ota-Setlik, Terry J. Higgins, Tracy Chen, Rong Xu, Janice M. Rusnak, Marc Tremblay, Susan E. Witko, Demetrius Matassov, Susan Sciotto-Brown, Luz Hermida, Cheryl S. Gerardi, John H. Eldridge
Publikováno v:
The Lancet. Infectious diseases. 20(4)
Summary Background The safety and immunogenicity of a highly attenuated recombinant vesicular stomatitis virus (rVSV) expressing HIV-1 gag (rVSVN4CT1-HIV-1gag1) was shown in previous phase 1 clinical studies. An rVSV vector expressing Ebola virus gly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b81da33fefbeb1d50c33bf76755e0d37
https://pubmed.ncbi.nlm.nih.gov/31952924
https://pubmed.ncbi.nlm.nih.gov/31952924